PepVax, Inc.

[Not Yet Scheduled]
PepVax, Inc. is an early-stage biotechnology company developing a DNA-based drug delivery and development platform. Our novel DNA plasmid delivery system takes a simplified method to delivery and our “Trojan Horse” approach uses the patient’s own cells to manufacture the required proteins, T-cells and antibodies inside the patient (Intusic™) for cancers, infectious and genetic diseases.

Manufacturing cell therapies, DNA, RNA and proteins ex vivo have always been a problem, especially in scale up and cost. With administration of externally manufactured drugs of these types, there are also strong possibilities for anti-drug-antibodies (ADAs) or over-acting immune responses leading to potential autoimmune reactions like cytokine storms. Our SMARTmid™ Vector is designed to take manufacturing from outside the patient to inside the patient, using the patient's own cells to manufacture the necessary protein-, DNA- and RNA-based treatments.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Maryland
Company HQ Country:
United States
Year Founded:
2013
Main Therapeutic Focus:
Lead Product in Development:
SMARTmid
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
PepVax, Inc.